United States Drug Patent 8,772,353: Scope, Claims, Expiration, Orange Book Status, and Ospemifene Patent Landscape

U.S. Patent No. 8,772,353 protects a food-associated dosing method for ospemifene, particularly administration of ospemifene with a nutritionally meaningful meal that stimulates bile-acid secretion and improves bioavailability. The strongest commercial embodiment is the 60 mg oral dose of Osphena, taken during or shortly after food, for dyspareunia associated with vulvar and vaginal atrophy in postmenopausal women.

The patent does not claim ospemifene as a chemical compound, a tablet composition, or the treatment of sexual dysfunction without the food-timing limitation. Its central limitation is the combination of:

Oral ospemifene administration;
Treatment of sexual dysfunction;
Administration in connection with food having nutritional value;
Food-induced bile-acid secretion; and
Enhanced ospemifene bioavailability.

The patent therefore has meaningful infringement value against a generic label that instructs patients to take ospemifene with food, but less reach against products or labels that omit the food instruction and rely on a bioequivalent formulation.

What does U.S. Patent 8,772,353 protect?

U.S. Patent 8,772,353 is a method-of-treatment patent directed to the pharmacokinetic use of ospemifene. Its claims focus on overcoming the drug’s food effect through administration with a meal.

Claim element	Scope
Active ingredient	Ospemifene or a pharmaceutically acceptable salt; claim 15 expressly recites ospemifene
Route	Oral administration
Disease category	Sexual dysfunction
Specific condition	Dyspareunia
Patient population	Perimenopausal or postmenopausal women
Food requirement	Foodstuff having nutritional value and causing bile-acid secretion
Pharmacologic result	Enhanced ospemifene bioavailability
Timing	From one hour before food begins through two hours after food begins
Narrow timing	During food intake through one hour after food begins; claim 4 narrows this to no later than 0.5 hour after food begins
Dose	30 to 90 mg/day, including 60 mg
Dosage form	Oral dosage form

The claims do not require the patent owner to prove a particular plasma concentration, area-under-the-curve value, or percentage increase in bioavailability in every patient. The claimed result is enhanced bioavailability, while the detailed timing and meal limitations define the method.

How do the independent claims differ?

Claims 1 and 15 are the two principal independent claims.

Claim 1 covers ospemifene or a pharmaceutically acceptable salt. Claim 15 recites ospemifene without the alternative salt language in the active-compound portion of the claim, although the claim text also refers to a pharmaceutically acceptable salt in the bioavailability clause.

Feature	Claim 1	Claim 15
Ospemifene	Yes	Yes
Pharmaceutically acceptable salt	Expressly included	Included in the claim’s bioavailability language
Sexual dysfunction	Required	Required
Food with nutritional value	Required	Required
Bile-acid secretion	Required	Required
Enhanced bioavailability	Required	Required
Specific timing	Not required in the independent claim	Not required in the independent claim
Dose	Not required	Not required
Dyspareunia	Not required	Not required
Menopausal status	Not required	Not required

A defendant could therefore face infringement exposure under claim 1 or claim 15 even if its label does not specify the 60 mg dose, dyspareunia, or postmenopausal women, provided the evidence supports the remaining limitations.

Which dependent claims create the principal commercial coverage?

Claims 2 through 14 add the timing, dosage, population, and indication limitations most closely aligned with the marketed product. Claims 16 through 19 provide a second set of narrower limitations under claim 15.

The commercially important claim combinations are:

Claim 4: administration during food intake or no later than 30 minutes after food begins;
Claim 6: 60 mg dosage;
Claim 8: dyspareunia;
Claim 11: 60 mg for a perimenopausal or postmenopausal woman with dyspareunia;
Claim 13: 60 mg oral dosing;
Claim 14: perimenopausal or postmenopausal woman;
Claim 18: 60 mg for dyspareunia;
Claim 19: perimenopausal or postmenopausal woman with dyspareunia.

Claims 11, 18, and 19 are particularly relevant to the FDA-approved Osphena use for moderate-to-severe dyspareunia associated with vulvar and vaginal atrophy.

What is the technical scope of the food limitation?

The food limitation is narrower than a generic requirement to take a tablet “with food.” The claim requires a foodstuff having nutritional value and causing secretion of bile acids. The specification and prosecution history are relevant to whether a particular snack, beverage, nutritional supplement, or low-calorie intake satisfies that limitation.

The limitation has three linked concepts:

Food must have nutritional value.
The food must cause bile-acid secretion.
The secretion must enhance ospemifene bioavailability.

A generic instruction to take ospemifene with a meal would create a strong infringement argument because the label may directly practice the claimed administration condition. A label that permits administration without food, or that instructs administration under fasting conditions, would reduce literal infringement risk. The patent owner could still examine induced infringement if the manufacturer’s promotional materials, patient instructions, or clinical materials encourage the patented food-associated regimen.

The bioavailability limitation may generate claim-construction disputes. The patent does not appear to require a fixed numerical increase. A court would likely examine the specification, expert testimony, and prosecution history to determine whether “enhance bioavailability” requires measurable improvement over fasting administration and how that improvement must be demonstrated.

What dosing and timing does Patent 8,772,353 cover?

The broadest timing window in claim 2 runs from one hour before food intake begins to two hours after food intake begins.

The narrower timing claims are:

Claim	Timing window
Claim 2	1 hour before food through 2 hours after food begins
Claim 3	During food intake through 1 hour after food begins
Claim 4	During food intake through no later than 0.5 hour after food begins
Claim 16	Same broad timing concept as claim 2

The dose claims cover 30 to 90 mg/day, with 60 mg expressly recited. This range encompasses the approved Osphena dose. A product labeled at 60 mg once daily with food would fall within the most commercially significant claim group if the other limitations are met.

The claims do not expressly require once-daily administration in every claim. A dosing schedule outside the claimed daily amount could avoid particular dependent claims, but it would not necessarily avoid the independent claims, which do not specify a dose.

When does U.S. Patent 8,772,353 lose exclusivity?

The patent issued on July 29, 2014. Its nominal term is governed by the U.S. patent-term statute, generally 20 years from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, terminal disclaimers, and other statutory modifications.[1]

Public patent records identify the patent as part of the ospemifene food-effect patent family. The practical expiration date must be taken from the USPTO patent-term calculation and applicable FDA Orange Book entry because the face-of-patent issue date does not determine expiration.

Event	Date or status
U.S. patent	8,772,353
Title	Method of treating sexual dysfunction
Issue date	July 29, 2014
Patent type	Method of treatment
Product association	Ospemifene, marketed as Osphena
Term basis	20-year term from applicable earliest effective filing date, subject to adjustments
Post-grant extensions	No assumption should be made without an official term calculation
Regulatory exclusivity	Separate from patent term

FDA Orange Book listings can change through patent-listing updates, delistings, certifications, litigation outcomes, or expiration events. The Orange Book should be checked against the current approved drug-product record before relying on the patent for launch timing.[2]

What is the Orange Book status of ospemifene?

Osphena is an FDA-approved oral ospemifene product. The approved indication is moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.[3]

The relevant regulatory structure includes:

Regulatory item	Status
Active ingredient	Ospemifene
Brand	Osphena
Dosage form	Oral tablet
Strength	60 mg
FDA pathway	New drug application
Approved use	Moderate-to-severe dyspareunia associated with vulvar and vaginal atrophy due to menopause
Product category	Small-molecule drug
Biosimilar pathway	Not applicable
Generic pathway	Abbreviated New Drug Application, subject to listed patents and regulatory exclusivity

Because ospemifene is a small molecule, future competition would proceed through the generic-drug pathway rather than the biosimilar pathway. An ANDA applicant could challenge listed patents through a Paragraph IV certification or make a Paragraph III certification that a patent will be respected until expiration.[4]

Which patent challenges and generic entry risks exist?

A generic ospemifene applicant would assess at least three possible strategies:

Paragraph IV challenge

The applicant could assert that Patent 8,772,353 is invalid, unenforceable, or not infringed. Likely arguments would focus on:

Whether administration with food and bile-acid secretion was obvious from known ospemifene food-effect data;
Whether the claims provide an unexpected pharmacokinetic benefit;
Whether “foodstuff having nutritional value” and “enhance bioavailability” are sufficiently definite;
Whether the claimed method is enabled across the full timing and dose ranges;
Whether the label necessarily induces practice of the patented method.

A Paragraph IV notice could trigger patent litigation and a 30-month stay of ANDA approval if statutory requirements are met.[4]

Skinny-label strategy

A generic applicant could attempt to omit patented use instructions from its labeling. This strategy is more difficult where the approved product’s dosing instructions require administration with food or where the remaining label would encourage the patented regimen.

The central issue would be whether the proposed label actively encourages the claimed food-associated method. The Federal Circuit’s induced-infringement decisions make label content, promotional materials, and the practical use of the generic product important evidence.[5]

Formulation or bioequivalence strategy

A generic manufacturer could develop a formulation that achieves bioequivalence without an instruction to administer with food. That approach could reduce exposure to the method claims, but it would require FDA approval based on the applicable bioequivalence pathway and might create formulation-development costs.

What other patents protect ospemifene?

The ospemifene estate has historically included several distinct patent categories:

Patent category	Typical subject matter	Relevance to generic entry
Compound patents	Ospemifene and related selective estrogen receptor modulators	Usually foundational but may expire earlier
Therapeutic-use patents	Treatment of vulvar and vaginal atrophy, dyspareunia, or sexual dysfunction	Can support label-based enforcement
Food-effect patents	Administration with food to improve bioavailability	Directly relevant to dosing instructions
Formulation patents	Tablets, excipients, release characteristics, or stability	Can create product-specific infringement risk
Manufacturing patents	Synthesis, purification, polymorphs, or intermediates	More difficult to enforce unless the generic uses the protected process
Regulatory patents	FDA-listed patents tied to the approved product	Can delay ANDA approval through certification and litigation

Patent 8,772,353 is strongest in the food-effect category. It does not independently establish ownership of the ospemifene molecule or every use of ospemifene for menopausal symptoms.

How strong is the patent estate for Osphena?

The estate is strongest where the marketed product, FDA label, and patent claims align. That alignment exists for:

60 mg oral dosing;
Administration with food;
Postmenopausal patients;
Dyspareunia;
Menopause-related vulvar and vaginal atrophy.

The estate is weaker against:

A formulation that avoids a food requirement;
A label that omits the patented use and does not encourage it;
Noninfringing manufacturing processes;
Uses outside sexual dysfunction or dyspareunia;
Dosing regimens outside the claimed ranges.

Patent 8,772,353 is a method patent, so its value depends heavily on the approved label and actual patient-use instructions. It is less resistant to design-around than a composition-of-matter patent because a competitor may target formulation, administration instructions, or labeling rather than reproduce the claimed method.

What litigation and settlement issues affect generic launch?

A Paragraph IV filing could lead to litigation under the Hatch-Waxman Act. The commercial sequence would generally be:

ANDA filing with a Paragraph IV certification;
Notice to the patent owner and NDA holder;
Patent litigation within the statutory period;
Potential 30-month approval stay;
Court decision, settlement, or expiration of the stay;
FDA approval subject to regulatory exclusivity and court orders.

No definitive settlement terms should be inferred solely from the existence of Patent 8,772,353. A settlement could provide a licensed launch date, a licensed manufacturer, or restrictions on label language. Such terms are material to generic-entry valuation and must be assessed from the filed agreement and court record rather than from patent-family data alone.

What revenue exposure does the patent create?

The patent’s revenue relevance is tied to the Osphena franchise, not to all ospemifene-related revenue. Exposure depends on:

Whether the patent remains listed and enforceable;
Whether a generic label must include food administration;
Whether the generic can obtain approval with a noninfringing label;
Whether other listed patents independently delay launch;
Whether a court grants an injunction or finds induced infringement;
Whether the generic launches at risk.

Patent 8,772,353 can support branded pricing during its enforceable term, but it is unlikely to provide the same exclusionary strength as a valid, unexpired compound patent. Its commercial leverage is greatest when combined with FDA labeling that directs patients to take 60 mg of ospemifene with food.

Key Takeaways

U.S. Patent 8,772,353 is a food-effect method patent for ospemifene.
The core invention is oral ospemifene administration with a nutritionally meaningful meal that stimulates bile-acid secretion and enhances bioavailability.
Claims 4, 6, 11, 18, and 19 closely track the commercial 60 mg Osphena regimen.
The patent does not claim ospemifene as a compound or every use of ospemifene.
Generic risk depends heavily on label language, food instructions, and induced-infringement evidence.
Ospemifene is a small molecule, so biosimilar analysis is not applicable.
A Paragraph IV challenge could attack validity, written description, enablement, definiteness, obviousness, or infringement.
The official USPTO term calculation and current FDA Orange Book record control the precise expiration and listing analysis.
Formulation and label design-arounds may reduce exposure but would require FDA-compliant approval strategies.
The patent is commercially important but narrower than a composition-of-matter patent.

FAQs

Is Patent 8,772,353 a composition-of-matter patent?

No. It is a method-of-treatment patent. It claims specified administration of ospemifene in connection with food to enhance bioavailability.

Does taking ospemifene with any snack infringe the patent?

Not necessarily. The claims require food having nutritional value and causing bile-acid secretion, together with enhanced ospemifene bioavailability. The facts concerning the food, timing, and pharmacokinetic effect would matter.

Does a 60 mg ospemifene tablet automatically infringe Patent 8,772,353?

No. The tablet alone is insufficient. Infringement requires practice of the claimed method, including oral administration for sexual dysfunction in connection with the specified food condition.

Can a generic avoid the patent by selling ospemifene without food instructions?

Potentially, but the analysis would depend on the proposed label, promotional conduct, actual intended use, and whether other listed patents cover the product or indication.

Is ospemifene subject to biosimilar competition?

No. Ospemifene is a small-molecule drug. Competition would proceed through the ANDA generic-drug pathway, not the biosimilar pathway.

References

United States Patent and Trademark Office. (n.d.). Patent term adjustment and patent term calculation. https://www.uspto.gov/patents/laws/adjustment
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
U.S. Food and Drug Administration. (2013). Osphena prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/
U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Patent certifications and 30-month stays. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda
U.S. Court of Appeals for the Federal Circuit. (2012). Takeda Pharmaceuticals U.S.A., Inc. v. West-Ward Pharmaceutical Corp., 785 F.3d 625.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1713458	⤷ Start Trial	CA 2015 00031	Denmark	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	C300742	Netherlands	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	92736	Luxembourg	⤷ Start Trial
European Patent Office	1713458	⤷ Start Trial	PA2015023	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,772,353

Summary for Patent: 8,772,353